| What Makes Sabesp (SBS) a Good Fit for 'Trend Investing' |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2025-05-16 13:51:09 |
Czytaj oryginał (ang.) |
| Here's Why 'Trend' Investors Would Love Betting on Sabesp (SBS) |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2025-04-30 13:50:50 |
Czytaj oryginał (ang.) |
| Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients |
Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI Congress ; Click here to register There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (TPN) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay This proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) PRIME program for expediated and assisted regulatory approval in the EU as well as FDA's Breakthrough Therapies program for expedited regulatory approval in the US SAN FRANCISCO, CA / ACCESS Newswire / April 30, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support (PS) in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption. |
accessnewswire.com |
2025-04-30 12:15:00 |
Czytaj oryginał (ang.) |
| REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) |
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today issued a reminder that Jaguar is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the initial results of the proof-of-concept investigator-initiated trial of a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates. Participation Instructions for Jaguar Investor Webcast When: Wednesday, April 30, 2025 at 8:30 AM Eastern Time Where: Online Registration link for conference: Click Here About Crofelemer Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. |
accessnewswire.com |
2025-04-29 20:15:00 |
Czytaj oryginał (ang.) |
| Sabesp: Market's Just Starting To Price The New Playbook |
SABESP is just beginning to unlock the benefits of privatization, with a bold R$70 billion investment plan through 2030 aimed at full sanitation coverage. Despite macro headwinds in Brazil, SBS ADRs have outperformed, buoyed by privatization momentum and significant operational upside. The stock still trades at an attractive EV/RAB of 1.22x, not fully reflecting future execution or asset base growth. |
seekingalpha.com |
2025-04-25 05:55:50 |
Czytaj oryginał (ang.) |
| Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress |
Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's PRIME program for novel medicines targeting unmet medical needs and the FDA's Breakthrough Therapies program SAN FRANCISCO, CA / ACCESS Newswire / April 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that preliminary results from the ongoing pediatric investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for various congenital diarrheal disorders (CDD), including MVID and SBS with intestinal failure (SBS-IF), will be presented by Dr. Mohamad Miqdady at the April 24-26, 2025 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates. MVID and SBS-IF, rare orphan diseases requiring intensive parenteral nutrition and support, have severe morbidity and mortality implications and impact the quality of life of both patients and their caregivers. |
accessnewswire.com |
2025-04-17 13:00:00 |
Czytaj oryginał (ang.) |
| 5 Must-Buy Efficient Stocks Amid Volatile Market Conditions |
Invest in companies like ALLT, SBS, LNN, EQBK and GFF to make the most of higher efficiency levels. |
zacks.com |
2025-04-17 11:55:31 |
Czytaj oryginał (ang.) |
| Growth Without The Premium: 6 Value Stocks For April |
In this period of extreme market turbulence, large-cap value stocks are outperforming large-cap growth stocks by nearly 8% YTD. This is a seismic shift in the style regime, as mega-cap growth has typically dominated performance. The Magnificent Seven are underperforming the S&P 500 on average -17.77% vs. -7.64% YTD. Value stocks have come into favor due to their defensive characteristics, hailing from sectors that are more resilient in economic downturns due to their essential nature. |
seekingalpha.com |
2025-04-16 09:00:00 |
Czytaj oryginał (ang.) |
| Sabesp (SBS) is on the Move, Here's Why the Trend Could be Sustainable |
Sabesp (SBS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2025-04-14 13:50:41 |
Czytaj oryginał (ang.) |
| Sabesp Q4: Privatization Is Making The Company More Agile Every Quarter (Rating Upgrade) |
I am upgrading my recommendation on Sabesp shares from hold to buy due to strong 4Q24 results, showing revenue and profit growth. Despite a lower EBIT due to redundancy provisions, Sabesp's operational efficiency post-privatization and healthy leverage position support a positive outlook. SBS stock is undervalued, trading at 5.4x EV/EBITDA versus a 5-year average of 6.56x, indicating a potential 21% upside. |
seekingalpha.com |
2025-03-26 10:37:54 |
Czytaj oryginał (ang.) |
| Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (SBS) Q4 2024 Earnings Call Transcript |
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (NYSE:SBS ) Q4 2024 Earnings Conference Call March 25, 2025 12:00 PM ET Company Participants Thiago Levy - Investor Relations Director Daniel Szlak - Chief Financial Officer and Investor Relations Officer Carlos Augusto Leone Piani - Chief Executive Officer Operator Good morning and welcome to SABESP Fourth Quarter of 2024 Earnings Presentation. With us here today are Carlos Piani, CEO; Daniel Szlak, CFO; and Thiago Levy, Investor Relations. |
seekingalpha.com |
2025-03-25 16:42:09 |
Czytaj oryginał (ang.) |
| Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF) |
This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions Availability of first IIT proof-of-concept results potentially in H1 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both SBS-IF and MVID SAN FRANCISCO, CA / ACCESS Newswire / February 19, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family companies Napo Pharmaceuticals ("Napo") and Napo Therapeutics today announced that the clinical protocol for Napo's Phase 2 study to evaluate the efficacy of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for the indication of SBS-IF in adults has received regulatory clearance from health authorities in Italy and Germany, where the trial will be conducted. The study initiated yesterday, February 18, 2025. |
accessnewswire.com |
2025-02-19 11:00:00 |
Czytaj oryginał (ang.) |
| Recent Price Trend in Sabesp (SBS) is Your Friend, Here's Why |
Sabesp (SBS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2025-02-17 11:51:18 |
Czytaj oryginał (ang.) |
| Sabesp (SBS) is a Top-Ranked Momentum Stock: Should You Buy? |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-03 12:55:53 |
Czytaj oryginał (ang.) |
| Are Utilities Stocks Lagging Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) This Year? |
Here is how Sabesp (SBS) and Telecom Italia (TIIAY) have performed compared to their sector so far this year. |
zacks.com |
2025-01-29 12:41:10 |
Czytaj oryginał (ang.) |
| Is Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) a Great Value Stock Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-07 13:06:50 |
Czytaj oryginał (ang.) |
| U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins |
The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder, in the US, EU, and/or Middle East/North Africa (MENA) regions; availability of IIT proof-of-concept results potentially in Q2 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that an independent IIT in the U.S. to evaluate the efficacy and safety of crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of short bowel syndrome with intestinal failure (SBS-IF) in adults has begun. An overview of the study can be viewed on the ClinicalTrials.gov website. |
accesswire.com |
2024-12-06 10:30:00 |
Czytaj oryginał (ang.) |
| Sabesp Q3: Good Result, But Macro Scenario Continues To Leave Me Skeptical |
Recommend holding Sabesp shares post-3Q24 results due to good trends, but valuation lacks safety margin amid Brazilian economic instability. Net revenues rose 9.6% y/y to $987 million, driven by tariff adjustments and privatization impacts on corporate accounting. Operating costs fell 3.1% y/y, with a strong EBITDA margin of 59.9%, and net income increased 43.7% y/y to $201 million. |
seekingalpha.com |
2024-12-05 00:08:38 |
Czytaj oryginał (ang.) |
| Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q3 2024 Earnings Call Transcript |
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (NYSE:SBS ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Luiz Tiberio - IR Superintendent Carlos Piani - CEO Daniel Szlak - Financial Director, Investor Relations Conference Call Participants Luiz Tiberio Good morning, everyone. My name is Luiz Roberto Tiberio. |
seekingalpha.com |
2024-11-12 16:45:11 |
Czytaj oryginał (ang.) |
| Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgroup analyses of the primary endpoint of the pivotal Phase III clinical trial, STARS, evaluating the treatment effect of apraglutide by baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure. |
businesswire.com |
2024-10-28 09:00:00 |
Czytaj oryginał (ang.) |
| 4 Stocks to Buy From the Promising Water Supply Industry |
Water utilities, AWK, SBS, AWR and SJW, are likely to benefit from stable demand for water and wastewater services. Capital-intensive utilities are set to gain from interest rate cuts. |
zacks.com |
2024-09-24 15:30:16 |
Czytaj oryginał (ang.) |
| Sabesp (SBS) Is a Great Choice for 'Trend' Investors, Here's Why |
Sabesp (SBS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2024-09-20 13:56:14 |
Czytaj oryginał (ang.) |
| Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) |
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan's Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO. |
accesswire.com |
2024-08-27 14:00:00 |
Czytaj oryginał (ang.) |
| Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) |
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Hong Kong's Intellectual Property Department has issued a new patent to Jaguar family company Napo Pharmaceuticals for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO. |
accesswire.com |
2024-08-19 14:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Sabesp (SBS) Should Keep going |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-08-19 13:50:52 |
Czytaj oryginał (ang.) |
| Here's Why Sabesp (SBS) is Poised for a Turnaround After Losing -11.66% in 4 Weeks |
Sabesp (SBS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2024-06-13 15:20:16 |
Czytaj oryginał (ang.) |
| SBS or GWRS: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Utility - Water Supply sector have probably already heard of Sabesp (SBS) and Global Water Resources, Inc. (GWRS). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2024-06-12 16:40:34 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-06-12 14:45:33 |
Czytaj oryginał (ang.) |
| Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 202. |
businesswire.com |
2024-05-21 10:00:00 |
Czytaj oryginał (ang.) |
| Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q1 2024 Earnings Call Transcript |
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (NYSE:SBS ) Q1 2024 Earnings Conference Call May 10, 2024 10:00 AM ET Company Participants Luiz Roberto Tiberio - IR Superintendent André Salcedo - CEO Catia Pereira - CFO and IR Officer Conference Call Participants Luiz Roberto Tiberio Hello. Good morning, everyone, and welcome to our earnings call for Q1 2024. |
seekingalpha.com |
2024-05-11 02:59:08 |
Czytaj oryginał (ang.) |
| What Makes Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) a Good Fit for 'Trend Investing' |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-03-26 11:51:07 |
Czytaj oryginał (ang.) |
| Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q4 2023 Earnings Call Transcript |
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-22 17:36:06 |
Czytaj oryginał (ang.) |
| SBS vs. GWRS: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Utility - Water Supply sector have probably already heard of Sabesp (SBS) and Global Water Resources, Inc. (GWRS). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2024-03-08 14:41:13 |
Czytaj oryginał (ang.) |
| Here's Why 'Trend' Investors Would Love Betting on Sabesp (SBS) |
Sabesp (SBS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2024-03-08 11:51:05 |
Czytaj oryginał (ang.) |
| Sabesp: Privatization Just Around The Corner, Q3 Results Still Provide Room For Upside |
Privatization of Brazilian water management company Sabesp is progressing, with a likely completion by the first half of 2024. The regulatory terms of the privatization will determine the company's long-term efficiency and potential for growth. The optimistic scenario envisions efficiency gains and a potential EV/RAB increase to 1.5x, suggesting a substantial upside. |
seekingalpha.com |
2023-11-30 08:29:01 |
Czytaj oryginał (ang.) |
| Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q3 2023 Earnings Call Transcript |
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (NYSE:SBS ) Q3 2023 Earnings Conference Call November 10, 2023 9:00 AM ET Company Participants Luiz Roberto Tiberio - Superintendent of IR Andre Salcedo - CEO Catia Pereira - CFO and IRO Conference Call Participants Luiz Roberto Tiberio Good morning, everyone. Welcome to the Earnings Conference Call for SABESP for the Third Quarter. |
seekingalpha.com |
2023-11-10 15:05:03 |
Czytaj oryginał (ang.) |